[Evaluation of an antioxidant and mitochondria-stimulating cream formula on the skin of patients with stable common vitiligo].
Vitiligo is a chronic illness of a yet unknown etiology, characterized by an acquired and progressive depigmentation of the skin. There are diverse treatments for this condition around the world, but up to now, none has been completely effective. The objective of this work was to evaluate the application of an antioxidant and mitochondrial stimulating formula, of topic use in leukodermic areas of patients with stable vulgar vitiligo. A clinical, experimental, randomized, double blind study was carried out in 50 male and 50 female patients with stable vulgar vitiligo. The patients were distributed in five groups as follows: Group 1 (labelled as VitilVenz AF): application of antioxidant and mitochondrial stimulating cream and oral administration of antioxidants and phenylalanine. Group 2 (labelled as Placebo AF): application of a placebo cream and oral administration of antioxidants and phenylalanine. Group 3 (labelled as without cream AF): oral administration of antioxidants and phenylalanine. Group 4 (labelled as Placebo cream): application of a placebo cream. Group 5 (labelled as VitilVenz): application of the antioxidant and mitochondrial stimulating cream. The following were measured in all patients: the clinical area of newly formed pigment every 30 days, during five months; and the presence of melanocytes in the histological study, at the beginning and at the end of treatment. The test of multiple comparison of Turkey-Kramer was used for the analysis of the results. The scheme of treatment that produced the best results was that of the Group 1, which consisted of the joint application of the antioxidant and mitochondrial stimulating cream and oral administration of antioxidants and phenylalanine (p < 0.001); followed by Group 5 that only received the topical treatment with the antioxidant and mitochondrial stimulating cream. The clinical and histological responses of these two groups (1 and 5) were significantly different to the rest of the groups. We concluded that the melanocytes in these patients could be in a dysfunctional state, product of the formation of free radicals that cause cellular and mitochondrial toxicity; and that these free radicals are removed by the antioxidant and mitochondrial stimulating elements present in the cream, turning the melanocytes functional and producing melanin in the achromic area of the vitiligo. This effect would be potentiated by the use of oral antioxidants and phenylalanine.
Rojas-Urdaneta
Janeth Elizabeth
JE
Departamento de Salud Púiblica, Núcleo Aragua, Maracay, Facultad de Ciencias de la Salud, Universidad de Carabobo, Venezuela. rujaneth@yahoo.com
Poleo-Romero
Abel Gustavo
AG
D000279:Administration, Cutaneous; D000284:Administration, Oral; D000975:Antioxidants / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D016166:Free Radical Scavengers / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008544:Melanocytes / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D008903:Minerals / Q000008:administration & dosage / Q000627:therapeutic use; D008928:Mitochondria / Q000187:drug effects*; D009824:Ointments; D018384:Oxidative Stress / Q000187:drug effects; D010649:Phenylalanine / Q000008:administration & dosage / Q000627:therapeutic use*; D028321:Plant Preparations / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D012867:Skin / Q000187:drug effects / Q000473:pathology; D012880:Skin Pigmentation / Q000187:drug effects; D014815:Vitamins / Q000008:administration & dosage / Q000627:therapeutic use; D014820:Vitiligo / Q000188:drug therapy* / Q000473:pathology
D000975:Antioxidants; D016166:Free Radical Scavengers; D008903:Minerals; D009824:Ointments; D028321:Plant Preparations; D014815:Vitamins; C520313:VitilVenz; D010649:Phenylalanine